Retinal Iron Homeostasis in Health and Disease
Retinal Iron Homeostasis in Health and Disease
批准号:
7889446
负责人:
VADIVEL GANAPATHY
金额:
$38.2万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-03-01 至 2014-02-28
关键词:
Acquired Immunodeficiency SyndromeAcute Retinal Necrosis SyndromeAddressAdolescentAffectAgeAge related macular degenerationAnimal ModelBMP2 geneBMP4BMP6 geneBlindnessBlood-Retinal BarrierBone Morphogenetic ProteinsBrainCataractCaucasiansCaucasoid RaceCell Differentiation processCell ProliferationCell Surface ProteinsCell physiologyCellsCeruloplasminCharacteristicsCodeComplement Factor HCytomegalovirusCytomegalovirus InfectionsDataDependenceDevelopmentDiseaseDown-RegulationDrusenE-CadherinEnzymesEpithelialEventExhibitsFarGoFrequenciesFunctional disorderGene ExpressionGenesGlaucomaGoalsHLA AntigensHealthHereditary DiseaseHereditary hemochromatosisHerpesvirus 1HistocompatibilityHomeostasisHumanIn VitroInfectionInjuryIronIron Metabolism DisordersIron OverloadIron-Regulatory ProteinsKidneyLaboratoriesLinkLiverMaintenanceMediatingMolecularMorphologyMuller&aposs cellMusMutateMutationNeural RetinaNutrientOrganOxidative StressPancreasPathogenesisPathologyPatientsPhenotypePhotoreceptorsPlayProliferative VitreoretinopathyProteinsRPE65 proteinRegulationRegulator GenesReportingRetinaRetinalRetinal DegenerationRetinal DiseasesRetinal Ganglion CellsRetinitisRoleSignal TransductionStem cellsStructureTestingTimeTissuesToxic effectTransgenic MiceTransplant RecipientsUp-RegulationVirusVirus DiseasesWild Type Mouseage relatedbasedesignepithelial to mesenchymal transitionganglion cellhepcidinin vivoinsightinterestmetal transporting protein 1mouse modelnoveloxidative damagepluripotencypublic health relevancereceptortranscription factortransferrin receptor 2
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The primary goal of this project is to test the hypothesis that retina is a target tissue for iron overload and iron-induced oxidative damage in hereditary hemochromatosis (HHC), the most prevalent genetic disease characterized by iron accumulation in systemic organs. Mutations in HFE [Histocompatability leukocyte antigen class I-like protein involved in iron (FE) homeostasis], a gene coding for a cell surface protein involved in the regulation of iron homeostasis, are responsible for ~85% cases of this disease (classical HHC). The remaining cases arise from mutations in four other genes (hemojuvelin, hepcidin, transferrin receptor 2, and ferroportin), also coding for iron-regulatory proteins. Mutations in hemojuvelin (HJV) cause juvenile HHC in which excessive iron accumulation occurs in organs at a much younger age than in classical HHC. Surprisingly, little is known on whether retina is affected in this disease. We have shown for the first time that all five HHC-associated genes are expressed in the retina: Hfe exclusively in RPE; Hjv in RPE and neural retina; hepcidin and ferroportin in RPE, Muller cells, and photoreceptor cells; and transferrin receptor 2 throughout the retina. More importantly, we have evidence for age-dependent morphological changes in the retina in a mouse model of classical HHC (Hfe-/- mouse). In addition, we found that Hfe-/- RPE cells exhibit a hyperproliferative phenotype compared to wild type RPE cells. These findings are novel and point to an interesting link between iron status and cell proliferation. Our studies also show that the expression of Hfe, Hjv, and hepcidin is markedly altered in RPE and in retina as a result of infection with cytomegalovirus (CMV) and herpes simplex virus-1 (HSV1). These interesting and important findings form the basis for the proposed studies. Aim 1 is to test the hypothesis that HHC is associated with iron overload in RPE and retina with functional consequences. This will be tested using two different mouse models, one representing the classical HHC (Hfe-/- mouse) and the other representing the juvenile HHC (Hjv-/- mouse). Aim 2 is to test the hypothesis that deletion of HFE and HJV has consequences that go far beyond iron accumulation and associated oxidative damage. Studies under this specific aim will include examination of the molecular events responsible for the hyperproliferative phenotype of Hfe-/- RPE cells as well as for the epithelial-to-mesenchymal transition in Hjv-/- RPE cells and for the disruption of BMP signaling and its consequences in Hjv-/- retina. Aim 3 is to test the hypothesis that infection of RPE and retina with CMV and HSV1 disrupts iron homeostasis by modulating the expression of iron-regulatory genes. This will be investigated using primary cultures of retinal cells in vitro and with wild type and HHC mouse models in vivo. These studies will provide important insight into the molecular mechanisms involved in the maintenance of iron homeostasis in the retina in health and disease and on the involvement of the retina in HHC, the most prevalent genetic disease in Caucasians.
PUBLIC HEALTH RELEVANCE: Hereditary hemochromatosis (HHC) is the most prevalent genetic disease characterized by excessive iron accumulation in various systemic organs, but whether the iron status in the retina is affected in this disease is not known. It is known however, that excessive iron accumulation in the retina causes oxidative damage and retinal degeneration. Studies proposed in this project will investigate the HHC-associated changes in the iron status, structure, and morphology of the retina and the functional consequences using transgenic mouse models of HHC, and assess the involvement of various iron-regulatory proteins in RPE and the retina during infection with cytomegalovirus and herpes simplex virus-1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Amino acid transporter SLC38A5 as a drug target for TNBC: Evaluation with genetic and pharmacologic approaches
-
批准号:10576760
-
项目类别:
-
资助金额:$21.46万
-
财政年份:2022
-
负责人:VADIVEL GANAPATHY
-
依托单位:
SLC5A8 is a conditional tumor suppressor in colon linked to dietary fiber content
-
批准号:9751215
-
项目类别:
-
资助金额:$33.93万
-
财政年份:2015
-
负责人:VADIVEL GANAPATHY
-
依托单位:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
-
批准号:8077946
-
项目类别:
-
资助金额:$15.51万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Retinal Iron Homeostasis in Health and Disease
-
批准号:8035342
-
项目类别:
-
资助金额:$35.55万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Retinal Iron Homeostasis in Health and Disease
-
批准号:8231427
-
项目类别:
-
资助金额:$35.56万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
"Starve the Tumor Cells to Death": SLC6A14 as a Drug Target for Colon Cancer
-
批准号:7963106
-
项目类别:
-
资助金额:$19.18万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Retinal Iron Homeostasis in Health and Disease
-
批准号:8423033
-
项目类别:
-
资助金额:$33.52万
-
财政年份:2010
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Molecular Analysis of a Novel Opioid Peptide Transporter
-
批准号:7230316
-
项目类别:
-
资助金额:$14.27万
-
财政年份:2006
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Molecular Analysis of a Novel Opioid Peptide Transporter
-
批准号:7127794
-
项目类别:
-
资助金额:$14.65万
-
财政年份:2006
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Immune Tolerance; Sigma Receptor as a Therapeutic Target
-
批准号:6352379
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2001
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Immune Tolerance; Sigma Receptor as a Therapeutic Target
-
批准号:6534340
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2001
-
负责人:VADIVEL GANAPATHY
-
依托单位:
Immune Tolerance; Sigma Receptor as a Therapeutic Target
-
批准号:6647090
-
项目类别:
-
资助金额:$21.53万
-
财政年份:2001
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6402792
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6527302
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6637291
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CARNITINE TRANSPORTERS: STRUCTURE, FUNCTION & REGULATION
-
批准号:6192658
-
项目类别:
-
资助金额:$25.55万
-
财政年份:2000
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CELLULAR TARGETS FOR ABUSABLE DRUGS IN HUMAN PLACENTA
-
批准号:2749122
-
项目类别:
-
资助金额:$25.31万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位:
POTOCYTOSIS AND PLACENTAL TRANSPORT FUNCTION
-
批准号:2673892
-
项目类别:
-
资助金额:$16.61万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位:
POTOCYTOSIS AND PLACENTAL TRANSPORT FUNCTION
-
批准号:2206798
-
项目类别:
-
资助金额:$15.45万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位:
CELLULAR TARGETS FOR ABUSABLE DRUGS IN HUMAN PLACENTA
-
批准号:2616075
-
项目类别:
-
资助金额:$4.63万
-
财政年份:1996
-
负责人:VADIVEL GANAPATHY
-
依托单位: